Could a fungal drug stop esophageal cancer before it starts?

NCT ID NCT06732388

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 5 times

Summary

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation. The goal is to see if the drug helps eliminate precancerous tissue faster and reduces the chance of cancer developing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baylor University Medical Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75246, United States

  • Case Western Reserve University

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44106, United States

  • UNC Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • University of Kansas Cancer Center

    NOT_YET_RECRUITING

    Kansas City, Kansas, 66160, United States

  • University of Michigan Rogel Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.